BEYOND THE EXTREME Digital Music Night Debuts_01.JPG

The audience enjoy the music.
The audience enjoy the music.

BEYOND THE EXTREME Digital Music Night Debuts_02.JPG

AI generated the realtime music captures.
AI generated the realtime music captures.

BEYOND THE EXTREME Digital Music Night Debuts_03.JPG

The guests watching the e-sports show on the screen.
The guests watching the e-sports show on the screen.

STOCKHOLM, Sept. 11, 2026 (GLOBE NEWSWIRE) — “BEYOND THE EXTREME – An Arctic Night of Digital Art & Electronic Music,” hosted by Perfect World Digital Art, officially opened at ICEBAR by ICEHOTEL in Stockholm. Set in a fully immersive -5°C ice environment, the event brought together Chinese intangible cultural heritage (ICH), esports, and cutting-edge Al technology, creating an audiovisual experience that transcended cultural, geographical, and temporal boundaries.

The event received special support from vrch.io, MirroS, and the organizing committee of the Perfect World Campus Art Design Award. As a key international cultural exchange initiative by Perfect World Digital Art, the event used the Arctic ice setting as a bridge between Nordic landscapes and Eastern cultural heritage. Traditional music from different regions of China, including Zhuang folk singing and Shaanxi Qinqiang opera, was reinterpreted through the lens of esports and AI. The evening’s centerpiece was a live ICH × Esports × AI audiovisual performance created by Perfect World Digital Art in collaboration with vrch.io. Drawing on Zhuang Laige, Mashan Zhuang three-part folk singing, the distinctive Zhuang wind instrument bóliè, and the powerful vocal tradition of Shaanxi Qinqiang opera, the performance preserved the authentic musical textures and cultural essence of these traditions while introducing the pioneering spirit of esports. Real-time visuals generated through vrch.io’s Agentic VJ system evolved dynamically with the music, merging sound, light, and space within the ice environment.

The event also featured a cross-cultural digital visual exhibition supported by MirroS, a partner of the Perfect World Campus Art Design Award. Built with the MirroS World Model, the short films combined Nordic landscapes with elements of traditional Chinese culture through a game-inspired, first-person journey from the Nordic environment toward the cultural landscapes of the East.

A representative of Perfect World Digital Art said the event explored new contemporary pathways for bringing traditional culture to international audiences through digital technology. Looking ahead, the team will continue to use digital art to build bridges between Eastern and Western cultures and bring Chinese cultural content to global audiences in increasingly technological and contemporary forms.

This press release is issued by Beijing Perfect World Software Technology Development Co., Ltd., part of the Perfect World corporate group.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/537a7f1e-8c41-4018-b2b0-04923a11e875

https://www.globenewswire.com/NewsRoom/AttachmentNg/e2af5202-a931-4e6e-b3f9-268a9035e2b8 

https://www.globenewswire.com/NewsRoom/AttachmentNg/43dedfb9-0171-481b-af9c-948446da3d9b

CONTACT: Eva Zhang
Pancartha AB
Jingyu.zhang@pancartha.se

September 11, 2026

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Interim results for the six months ended June 30, 2026

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today announces its unaudited interim results for the six months ended June 30, 2026 which will also be made available on the Company’s website at https://biodexapharma.com/ .

OPERATIONAL HIGHLIGHTS

The Company announced the following in the six months ended June 30, 2026:

  • In-license of MTX240 (formerly OPB-171755) from Otsuka Pharmaceutical Co., Limited in February 2026 with a nominal upfront payment.
  • Launch of a global Early Access Program for eRapa for FAP Patients through a strategic partnership with Tanner Pharma Group in March 2026.
  • Approval from Health Canada to expand the Serenta trial into Canada in June 2026.
  • Promotion of Fiona Sharp to Chief Financial Officer and Company Secretary, also joining the Board of Directors from January 2026.

Post period end:

  • On July 1, 2026, the Company completed a fundraise raising gross proceeds of $3.5 million through a combination of a registered direct offering, warrant inducement and PIPE offering.
  • As of the date of publication, 92 subjects, of a planned 168 subjects, have been enrolled in the Serenta trial.

FINANCIAL HIGHLIGHTS

  • R&D costs increased to £2.92 million in 1H26 (1H25: £1.67 million) reflecting increased expenditure on the Serenta trial and manufacturing costs on the newly in-licensed MTX240 program.
  • Administrative costs decreased to £1.74 million (1H25: £2.38 million) primarily as a result of foreign exchange movements.
  • Net cash used in operating activities (after changes in working capital) in 1H26 was £4.61 million (1H25: £3.30 million).
  • The Company’s cash balance at June 30, 2026 was £3.23 million.

Commenting, Stephen Stamp, CEO , said “We accomplished two main things in the first six months.

First, building on the advice we received from regulators, we accelerated enrolment into our registrational Phase 3 trial of eRapa in FAP. There are no approved therapeutics for FAP and passing the 50% enrolment in early August puts us significantly ahead of any competitive development programs.

Second, in-licensing MTX240 for GIST rounds out our GI cancer portfolio and, given its unique mechanism of action, has the potential to treat GIST patients irrespective of their KIT or PDGFR mutation. The Phase 1b/2a trial we are working to initiate is designed to establish a safe and effective dose as well as an efficacy signal before the end of 2027.

As always, financing remains a challenge for companies of our size.”

CHIEF EXECUTIVE’S REVIEW

Our main focus in the first half of 2026 was on (1) expanding our registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (“FAP”) in Europe, and (2) initiating activities for the re-start of a Phase 1 trial of MTX240 in gastrointestinal stromal tumors (“GIST”) which was in-licensed in early February 2026.

R&D update

In the first half of 2026 we progressed our Phase 3 trial of eRapa in FAP and added MTX240, a novel Phase 1 ready asset for the treatment of GIST. As of today, we have two active sponsored programs and two investigator initiated programs:

MTX230 – eRapa

eRapa is a proprietary oral formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035.

Familial Adenomatous Polyposis
FAP is characterized by a proliferation of polyps in the colon, duodenum and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the gastrointestinal tract remain the standard of care. If untreated, FAP almost always leads to colorectal cancer. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP There is a significant hereditary component to FAP with a reported incidence of one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe. eRapa has received Orphan Designation in the US and in Europe.

Following encouraging results from an open label Phase 2 study, a Type C meeting with the FDA and scientific advice from the EMA, we initiated a registrational Phase 3 trial (NCT06950385) of eRapa in June 2025. The trial, branded “Serenta” is a double-blind placebo-controlled design, recruiting 168 high risk subjects diagnosed with germline or phenotypic FAP. The primary clinical endpoint is first progression free survival event which will comprise composite endpoints including major surgery. As of the date of publication, 92 subjects have been recruited in the trial across 19 centers in the US and 10 centers in five European countries. Two centers in Canada are expected to begin enrolling in 4Q26.

Non-muscle Invasive Bladder Cancer (“NMIBC”)
NMIBC refers to tumors found in the tissue that lines the inner surface of the bladder. The most common treatment is transurethral resection of the bladder tumor followed by intravesical Bacillus Calmette-Guerin (“BCG”) with chemotherapy depending upon assessment of risk of recurrence. NMIBC is the fourth most common cancer in men with an incidence of 10.1 per 100,000 and 2.5 per 100,000 in women.

The ongoing investigator initiated two-center, double-blind, placebo-controlled Phase 2 trial in NMIBC (NCT04375813) is fully enrolled at 166 patients with primary endpoints of safety/tolerability and relapse free survival after 12 months of treatment. The study, which is supported by a $3.0 million non-dilutive grant from the National Cancer Institute, part of the National Institutes of Health, is expected to read out in Q426.

MTX240 – molecular glue

We in-licensed global rights (excluding Japan) to MTX240 from Otsuka Pharmaceutical Co, Limited (“Otsuka”) in early February 2026. Discovered by Otsuka and originally coded OPB-171755, MTX240 is a novel molecular glue we intend to develop for the treatment of GIST. Its unique mechanism of action brings together two intracellular proteins, PDE3A and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT or PDGFR signaling. GIST is mostly driven by activating mutations in the KIT receptor tyrosine kinase. Although tyrosine kinase inhibitors (“TKIs”) such as imatinib, sunitinib, and regorafenib have significantly improved outcomes for GIST patients, resistance almost always develops through secondary KIT or PDGFR mutations or activation of alternative signaling pathways. This represents a substantial clinical challenge with limited therapeutic options for patients once they have cycled through the available TKIs. Molecular glue technology represents a novel approach that induces targeted protein interactions, offering a distinct mechanism of action to conventional kinase inhibitors for GIST and by triggering cell death through an alternative pathway MTX240 is designed to overcome the resistance mechanisms that render TKI-resistant GISTs refractory to conventional kinase inhibitors.

Gastrointestinal Stromal Tumors (GIST)
GIST is a rare gastrointestinal malignancy affecting approximately 3,000-4,000 patients annually in the US, with a significant unmet medical need for patients who develop TKI resistance. Approximately 10-15% of GIST patients are either primarily refractory, or develop secondary resistance to available TKIs whereupon options for these patients remain limited.

The global GIST market is valued at approximately $1.3 billion and is expected to grow at 6-10% annually through 2032, driven by rising incidence and emerging therapeutic options targeting treatment-resistant disease.

GIST qualifies for orphan drug designation in major regulatory jurisdictions, offering potential regulatory advantages and incentives to support drug development.

We are in the process of initiating activities for the re-start of a Phase 1 dose escalation and dose optimization trial, most likely an open label trail in GIST patients with no available therapeutic options. GMP clinical trial supplies are being developed and manufactured by Syngene International Limited. In the meantime, we are preparing regulatory submissions for a pre-IND meeting with the FDA.

MTD228 – Tolimidone

Tolimidone was originally discovered by Pfizer and was developed through Phase 2 for the treatment of gastric ulcers. Tolimidone is a selective activator of the enzyme Lyn kinase which increases phosphorylation of insulin substrate-1, thereby amplifying the signaling cascade initiated by the binding of insulin to its receptor.

Type 1 Diabetes (“T1D”)
Tolimidone’s potential utility in T1D has been demonstrated by several preclinical studies conducted by the University of Alberta, where Lyn kinase was identified as a key factor for beta cell survival and proliferation in in vitro and in vivo models. Tolimidone appeared to induce proliferation in beta cells isolated from human cadavers. In a meta analysis of 1,202 articles and 193 studies, the incidence of T1D was shown to be 15 per 100,000 with a prevalence of 9.5 per 10,000 of the population.

An ongoing Phase 2a investigator initiated trial at the University of Alberta Diabetes Institute (NCT06474598) is designed to establish the minimum effective dose of tolimidone in patients with T1D. The study enrolled the first patient in June 2025 and is expected to recruit 12 patients initially across three dose groups. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events.

1H26 FINANCIAL REVIEW

The unaudited results for the six months ended June 30, 2026 are discussed below:

Key performance indicators (KPIs):

  1H 2026 1H 2025 Change
       
R&D costs £2.92m £1.67m 75%
R&D as % of operating costs 63% 41% n/a
Net cash inflow/(outflow) for the period (£5.31m) £2.37m n/m
       

Biodexa’ s KPIs focus on the key areas of operating results, R&D spend and cash management. These measures provide information on the core R&D operations. Additional financial and non-financial KPIs may be adopted in due course.

Revenues

Revenue for both periods was £Nil. The last of the Company’s R&D collaborations concluded in September 2023.

Research and Development

R&D costs for 1H26 and 1H25, analyzed by development project indication were as follows:

Six months ended June 30 2026 2025
    £’000 £’000
eRapa    
  Familial Adenomatous Polyposis 1,420 251
  Non-muscle Invasive Bladder Cancer 2 127
Total eRapa 1,422 378
       
MTX240    
  GIST 295 –
Total MTX240 295 –
     
Tolimidone    
  Type 1 Diabetes 49 270
Total tolimidone 49 270
       
MTX110 (Panobinostat)    
  Diffuse Midline Glioma – –
  Recurrent Glioblastoma 155 14
  Medulloblastoma – –
Total MTX110 (Panobinostat) 155 14
       
Other preclinical – 1
       
R&D overheads 995 1,002
       
Total R&D 2,916 1,665

MTX230 eRapa Familial Adenomatous Polyposis costs are shown above net of grant income. For the six months ended June 30, this is analyzed as follows:

For period to 30 June 2026 2025
    £’000 £’000
       
  Grant income (2,818) (2,107)
  Gross costs 4,238 2,358
Net charge to income statement 1,420 251
     
  % costs allocated against CPRIT grant 66% 89%

R&D costs in 1H26 increased by £1.25 million, or 75%, to £2.92 million compared with £1.67 million in 1H25. R&D costs as a percentage of total operating costs increased to 63% from 41%. The increase was predominantly due to increased activity on the MTX230 Serenta clinical trial, which increased by £1.04 million, and manufacturing costs on the Company’s new MTX240 program of £0.30 million. The percentage of MTX230 (eRapa) costs offset against grant funding during the period was 66%, compared with 89% in 1H25. The Company anticipates that this percentage will be 67% over the life of the grant.

Administrative Costs

Administrative costs in 1H26 decreased by £0.64 million, or 27%, to £1.74 million from £2.38 million in 1H25. The decrease was driven primarily by foreign exchange movements, with a gain of £0.08 million recognized in 1H26 compared with a charge of £0.40 million in 1H25. Professional fees also decreased by £0.12 million in the period.

Finance Income and Expense

Finance income in 1H26 included gains in respect of an equity-settled derivative financial liability of £2.38 million (1H25: £0.15 million). The gains arose as a result of the fall in the Biodexa share price. In addition, the Company earned interest on cash deposits.

Finance expense in the period related to lease liabilities and discounted interest on deferred consideration.

Cash Flows

Cash outflows from operating activities in 1H26 were £4.61 million compared to £3.30 million in 1H25, driven by a net loss of £1.84 million (1H25: £3.81 million) and after negative working capital of £0.55 million (1H25: negative £0.04 million) and other negative non-cash items totaling £2.22 million (1H25: positive £0.24 million).

Net cash used in investing activities in 1H26 was £0.63 million (1H25: outflow of £0.34 million). This comprised £0.71 million of cash outflows relating to the purchase of the MTX240 license from Otsuka for total consideration of £0.37 million and the payment of deferred consideration on the eRapa license of £0.34 million (1H25: £0.37 million), offset by £0.09 million of interest received (1H25: £0.04 million).

Net cash used in financing activities in 1H26 was £0.07 million (1H25: inflow of £6.01 million), reflecting payments on lease liabilities.

Overall, cash decreased by £5.31 million in 1H26 compared with an increase of £2.37 million in 1H25. This resulted in a cash balance at June 30, 2026 of £3.23 million compared with £4.04 million at June 30, 2025 and £8.53 million at December 31, 2025.

Financing

On June 30, 2026, the Company entered into a securities purchase agreement utilizing its Registration Statement on Form F-3 to issue 82,809 ADSs and 200,143 pre-funded ADS warrants. In a concurrent Private Placement the Company agreed to issue 350,877 pre-funded ADS warrants. Each ADS was sold at an offering price of US$2.85, and each Pre-Funded Warrant was sold at an offering price of US$2.8499. In connection with the securities purchase agreement the Company agreed, upon receipt of Shareholder Approval, to issue 282,952 Series M Warrants and 701,754 Series N Warrants. The Series M and Series N Warrants have an exercise price of US$2.85 per ADS and have a term of five years from the date Shareholder Approval is obtained.

In addition, the Company entered into a warrant exercise inducement letter with a holder of Series L Warrants to purchase 609,756 ADSs at a reduced exercise price of US$2.85 per ADS. In consideration, the Company agreed, upon receipt of Shareholder Approval, to issue Series O Warrants to purchase an aggregate of 1,219,512 ADSs upon exercise of the existing warrants. The Series O Warrants have an exercise price of US$2.85 per ADS and a term of five years from the date Shareholder Approval is obtained.

The above transactions completed on July 1, 2026 and raised $3.5 million of gross proceeds.

Going concern

Biodexa has experienced net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For the six months to June 30, 2026, the Group incurred a consolidated loss of £1.84 million (1H25: £3.81 million) and negative cash flows from operating activities of £4.61 million (1H25: £3.30 million). As of June 30, 2026, the Group had accumulated deficit of £157.60 million.

The Group’s future viability is dependent on its ability to raise cash from financing activities to finance its development plans until milestones and/or royalties can be secured from partnering the Company’s assets. The Group’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.

The Directors believe there are adequate options and time available to secure additional financing for the Group and after considering the uncertainties, the Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. The Group’s consolidated financial statements have therefore been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

As at June 30, 2026, the Group had cash and cash equivalents of £3.23 million. On July 1, 2026, the Company completed the financing transaction described above, raising gross proceeds of $3.5 million. The Directors have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period 12 months from the date of approval of this interim financial information. These forecasts show that further financing will be required during Q4 2026 assuming, inter alia, that certain development programs and other operating activities continue as currently planned. Pursuant to its $35 million Equity Line of Credit (“ELOC”) entered into in 2025, the Company may direct C/M to purchase ADSs (subject to certain limitations) and receive proceeds in accordance with a formula price. There is no guarantee that the Company will be able to use the ELOC or raise from other financing to the extent necessary to finance the Company’s operations. As at 30 June 2026 $26.08 million remains undrawn from the ELOC.

In the Directors’ opinion, the environment for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa are likely to be dilutive. The Directors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of alternative courses of action to finance the Group would be successful.

The Directors have also considered the potential impact of Nasdaq’s proposed minimum market value requirement. Although implementation of the proposed rule has been stayed pending full Commission review, Biodexa’s current market capitalization is below the announced $5 million threshold. If implemented, or if the Company otherwise failed to maintain compliance with Nasdaq listing requirements, this could adversely affect the Company’s ability to raise funds, reduce investor appetite and limit the strategic value of the Company’s Nasdaq listing in connection with potential merger or reverse merger opportunities.

This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group’s ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Group which are actionable before its cash resources run out, the Group will no longer be a going concern. In such circumstances, the Group would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis, assets would be stated at net realizable value, and liabilities would be accelerated to current liabilities.

Stephen Stamp
Chief Executive Officer

Consolidated Statements of Comprehensive Income
For the six month period ended June 30

  Note 2026
unaudited
£’000
2025
unaudited
£’000
Revenue   – –
Other income   444 27
Research and development costs   (2,916) (1,665)
Administrative costs   (1,738) (2,378)
Loss from operations   (4,210) (4,016)
Finance income 3 2,474 180
Finance expense 3 (62) (135)
Loss before tax   (1,798) (3,971)
Taxation   (44) 165
Loss for the period attributable to the owners of the parent   (1,842) (3,806)
Items that will or may be reclassified subsequently to profit or loss:      
Exchange (loss)/gains arising on translation of foreign operations   (3) 3
Total comprehensive loss attributable to the owners of the parent   (1,845) (3,803)
Loss per share      
Basic and diluted loss per ordinary share – £ 4 £(0.000005) £(0.0002)

The accompanying notes form part of these financial statements

Consolidated Statements of Financial Position

    Note As at
June 30, 2026 unaudited
£’000
As at
December 31, 2025
£’000
Assets        
Non-current assets        
Property, plant and equipment     20 91
Intangible assets   5 6,011 5,645
      6,031 5,736
Current assets        
Trade and other receivables     2,935 3,786
Taxation     525 123
Cash and cash equivalents     3,230 8,534
      6,690 12,443
Total assets     12,721 18,179
Liabilities        
Non-current liabilities        
Deferred consideration     331 645
Borrowings     – –
      331 645
Current liabilities        
Trade and other payables     1,636 2,590
Deferred consideration     609 563
Borrowings     – 61
Derivative financial liability     532 2,915
      2,777 6,129
Total liabilities     3,108 6,774
Issued capital and reserves attributable to owners of the parent        
Share capital   6 14,246 14,099
Share premium     99,790 98,923
Merger reserve     53,003 53,003
Warrant reserve     174 1,185
Foreign exchange reserve     – 3
Accumulated deficit     (157,600) (155,808)
Total equity     9,613 11,405
Total equity and liabilities     12,721 18,179

The accompanying notes form part of these financial statements

Consolidated Statements of Cash Flows
For the six month period ended June 30

  Note 2026
unaudited
£’000
2025
unaudited
£’000
Cash flows from operating activities      
Loss for the period   (1,842) (3,806)
Adjustments for:      
Depreciation of property, plant and equipment   11 70
Depreciation of right of use asset   68 69
Amortization of intangible fixed asset   – 1
Impairment of commission paid in advance on ELOC   – 373
Finance income 3 (2,474) (180)
Finance expense 3 62 135
Share-based payment expense   50 97
Taxation   44 (165)
Foreign exchange losses   22 (157)
Cash flows from operating activities before changes in working capital   (4,059) (3,563)
Decrease/(Increase) in trade and other receivables   405 2,047
(Decrease)/Increase in trade and other payables   (957) (2,090)
Cash used in operations   (4,611) (3,606)
Tax receipts   – 302
Net cash used in operating activities   (4,611) (3,304)

Consolidated Statements of Cash Flows (continued)
For the six month period ended June 30

  Note 2026
unaudited
£’000
2025
unaudited
£’000
Investing activities      
Purchases of property, plant and equipment   (7) (2)
Purchase of intangible assets 5 (713) (372)
Interest received   90 35
Net cash generated from/(used in) investing activities   (630) (339)
Financing activities      
Interest paid   (3) (10)
Amounts paid on lease liabilities   (62) (95)
Repayment of Promissory Note   – (136)
Share issues including warrants, net of costs 6 – 6,251
Net cash generated from/(used in) financing activities   (65) 6,010
Net increase/(decrease) in cash and cash equivalents   (5,306) 2,367
Cash and cash equivalents at beginning of period   8,534 1,669
Exchange (losses)/gains on cash and cash equivalents   2 –
Cash and cash equivalents at end of period   3,230 4,036

The accompanying notes form part of these financial statements

Consolidated Statements of Changes in Equity (unaudited)

  Note Share
capital
£’000
Share
premium
£’000
Merger reserve
£’000

Warrant reserve £’000

Foreign exchange reserve £’000 Accumulated
deficit
£’000
Total
equity
£’000
At January 1, 2026   14,099 98,923 53,003 1,185 3 (155,808) 11,405
Loss for the period   – – – – – (1,842) (1,842)
Foreign exchange translation   – – – – (3) – (3)
Total comprehensive loss   – – – – – (1,842) (1,845)
Transactions with owners:                
Warrant exercise   147 867 – (1,011) – – 3
Share-based payment charge   – – – – – 50 50
Total contribution by and distributions to owners   147 867 – (1,011) – 50 53
At June 30, 2026   14,246 99,790 53,003 174 – (157,600) 9,613

  Note Share
capital
£’000
Share
premium
£’000
Merger reserve
£’000

Warrant reserve £’000

Foreign exchange reserve £’000 Accumulated
deficit
£’000
Total
equity
£’000
At January 1, 2025   11,725 93,124 53,003 894 – (150,424) 8,322
Loss for the period   – – – – – (3,806) (3,806)
Foreign exchange translation   – – – – 3 – 3
Total comprehensive loss   – – – – 3 (3,806) (3,803)
Transactions with owners:                
Shares issued under ELOC agreement 6 2,024 4,551 – – – – 6,575
Costs associated with ELOC agreement   86 (76) – – – – 10
Shares issued on 15 May 2025 6 100 143 – – – – 243
Costs associated with share issue on 15 May 2025   – (8) – – – – (8)
Share-based payment charge   – – – – – 97 97
Total contribution by and distributions to owners   2,210 4,610       97 6,917
At June 30, 2025   13,935 97,734 53,003 894 3 (154,133) 11,436

The accompanying notes form part of these financial statements

  

Notes Forming Part of The Consolidated Unaudited Interim Financial Information
For the six month period ended June 30, 2026

1.    Basis of preparation

The unaudited interim consolidated financial information for the six months ended June 30, 2026 has been prepared following the recognition and measurement principles of the International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively IFRS) issued by the International Accounting Standards Board (IASB), and as adopted by the UK and in accordance with International Accounting Standard 34 Interim Financial Reporting (‘IAS 34’). The interim consolidated financial information does not include all the information and disclosures required in the annual financial information and should be read in conjunction with the audited financial statements for the year ended December 31, 2025.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting periods.

Book values approximate to fair value at June 30, 2026, June 30, 2025 and December 31, 2025.

The condensed interim financial information contained in this interim statement does not constitute statutory financial statements as defined by section 434(3) of the Companies Act 2006. The condensed interim financial information has not been audited. The comparative financial information for the six months ended June 30, 2025 and the year ended December 31, 2025 in this interim financial information does not constitute statutory financial statements for that period or year. The statutory financial statements for December 31, 2025 have been delivered to the UK Registrar of Companies. The auditor’s report on those accounts was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006. The auditor’s report did draw attention to a material uncertainty related to going concern and the requirement, as of the date of the report, for additional funding to be raised by the Company in the third quarter of 2026.

Biodexa Pharmaceutical’s annual reports may be downloaded from the Company’s website at    https://biodexapharma.com/investors/financial-reports-and-presentations/#financial-reports or a copy may be obtained from 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ.

Going Concern – material uncertainty

Biodexa has experienced net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For the six months to June 30, 2026, the Group incurred a consolidated loss of £1.84 million (1H25: loss £3.81 million) and negative cash flows from operating activities of £4.61 million (1H25 £3.30 million). As of June 30, 2026, the Group had accumulated deficit of £157.60 million.

The Group’s future viability is dependent on its ability to raise cash from financing activities to finance its development plans until milestones and/or royalties can be secured from partnering the Company’s assets. The Group’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.

The Directors believe there are adequate options and time available to secure additional financing for the Group and after considering the uncertainties, the Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. The Group’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

As at June 30, 2026, the Group had cash and cash equivalents of £3.23 million. On July 1, 2026, the Company completed the financing transaction described above, raising gross proceeds of $3.5 million. The Directors have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period 12 months from the date of approval of this interim financial information. These forecasts show that further financing will be required during Q4 2026 assuming, inter alia, that certain development programs and other operating activities continue as currently planned. Pursuant to its $35 million Equity Line of Credit (“ELOC”) entered into in 2025, the Company may direct C/M to purchase ADSs (subject to certain limitations) and receive proceeds in accordance with a formula price. There is no guarantee that the Company will be able to use the ELOC or raise from other financing to the extent necessary to finance the Company’s operations. As at 30 June 2026 $26.08 million remains undrawn from the ELOC.

In the Directors’ opinion, the environment for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa are likely to be dilutive. The Directors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of alternative courses of action to finance the Company would be successful.

The Directors have also considered the potential impact of Nasdaq’s proposed minimum market value requirement. Although implementation of the proposed rule has been stayed pending full Commission review, Biodexa’s current market capitalization is below the announced $5 million threshold. If implemented, or if the Company otherwise failed to maintain compliance with Nasdaq listing requirements, this could adversely affect the Company’s ability to raise funds, reduce investor appetite and limit the strategic value of the Company’s Nasdaq listing in connection with potential merger or reverse merger opportunities.

This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group’s ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Group which are actionable before its cash resources run out, the Group will no longer be a going concern. In such circumstances, the Group would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis, assets would be stated at net realizable value, and liabilities would be accelerated to current liabilities.

2.   Accounting for eRapa and CPRIT grant

On 25 April 2024 the Company entered into a License and Collaboration Agreement (LCA) with Rapamycin Holdings, Inc. (d/b/a Emtora Biosciences). The LCA entered into with Emtora meets the definition of a Joint Arrangement under IFRS 11, specifically related to the FAP program.

A jointly controlled escrow account was established on completion of the LCA. FAP program transactions eligible to be allocated against the CPRIT grant and match funding are processed through the escrow account, including the Company’s deposits of matching funds, as set out in the agreement, the receipt of grant funding from CPRIT and the payment of eligible R&D expenses. Although the CPRIT grant and R&D supplier contracts are with Emtora, the joint arrangement nature of the LCA results in Emtora being deemed to be acting as the Company’s agent. Accordingly, the Company recognizes 100% of the grant and 100% of the R&D expenditure. The CPRIT grant recognized is on a 1 for 2 match basis for the first $17 million, the final $3 million is recognized on a 1 for 1 basis. In accordance with the Company’s accounting policy, the grant, as it is the re-imbursement of directly related costs, is credited to R&D costs in the same period in the Statements of Comprehensive Income. The escrow account is recognized within prepayments, CPRIT grant received in advance is recognized within deferred revenue and any grant not yet received is recognized in accrued income.

The balances at the reporting date were as follows:

  June 30,2026
£’000
December 31, 2025
£’000
Prepayments* 527 2,842
Accrued revenue 332 –
Deferred revenue – 571

* prepayment reflects only the escrow account balance

3.   Finance income and expense

  Six months ended June 30, 2026
unaudited
£’000
Six months ended June 30, 2025
unaudited
£’000
Finance income    
Interest received on bank deposits 91 32
Other interest – 3
Gain on equity settled derivative financial liability 2,383 145
Total finance income 2,474 180

The gain on the equity settled derivative financial liability in 1H26 and 1H25 arose as a result of the fall in the Biodexa share price.

  Six months ended June 30, 2026
unaudited
£’000
Six months ended June 30, 2025
unaudited
£’000
Finance expense    
Interest expense on lease liabilities 1 6
Interest expense on deferred consideration 57 86
Other loans – 43
Other 4 –
Total finance expense 62 135

4.   Loss per share

Basic loss per share amounts are calculated by dividing the net loss for the period from continuing operations, attributable to ordinary equity holders of the parent company, by the weighted average number of ordinary shares outstanding during the period. As the Group made a loss for the period the diluted loss per share is equal to the basic loss per share.

  Six months ended June 30, 2026
unaudited
£’000
Six months ended June 30, 2025
unaudited
£’000
Numerator    
Loss used in basic EPS and diluted EPS: (1,842) (3,806)
Denominator    
Weighted average number of ordinary shares used in basic EPS 373,230,692,484 25,267,266,823
     
Basic and diluted loss per share: £(0.000005) £(0.0002)

5.   Intangible asset

  In-process research and development
£’000
Goodwill
£’000
IT/Website costs
£’000
Total
£’000
Cost        
At January 1, 2026 19,023 2,291 69 21,383
Acquisition 366 – – 366
At June 30, 2026 (unaudited) 19,389 2,291 69 21,749
  In-process
research and
development
£’000
Goodwill
£’000
IT/Website
Costs
£’000
Total
£’000
Accumulated amortization and impairment        
At January 1, 2026 13,378 2,291 69 15,738
Amortization charge for the period – – – –
At June 30, 2026 (unaudited) 13,378 2,291 69 15,738
Net book value        
At June 30, 2026 (unaudited) 6,011 – – 6,011

On February 4, 2026, the Company announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. A novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumors (GIST). The compound also has the potential to be useful in additional indications. In the Company’s pipeline, OPB-171775 is coded MTX240.

Under the terms of the license agreement the Company has the exclusive rights to develop and commercialize MTX240 globally with the exception of Japan where Otsuka retains its rights. The agreement includes an upfront cash fee of $500,000 and additional development and regulatory milestones. In addition, tiered royalties in the mid-single digit range are payable on net sales of MTX240.

The individual intangible asset which is material to the financial statements is as follows:

  Carrying amount
As at June 30, 2026
£’000
As at December 31, 2025
£’000
MTX228 tolimidone acquired IPRD* 2,938 2,938
MTX230 eRapa acquired IPRD* 2,707 2,707
MTX240 acquired IPRD* 366 –

*asset is not yet in use and has not started amortizing

6.   Share capital and reserves

Authorized, allotted and fully
paid – classified as equity

As at June 30, 2026 unaudited
Number
As at June 30, 2026 unaudited
£
As at December
31, 2025
Number
As at December 31, 2025
£

Ordinary shares of £0.000001 each

373,056,808,922
373,057
225,817,808,922
225,818

‘A’ Deferred shares of £1 each

1,000,001
1,000,001
1,000,001
1,000,001

‘B’ Deferred shares of £0.001 each

4,063,321,418
4,063,321
4,063,321,418
4,063,321

‘C’ Deferred shares of £0.00005 each 4,063,321,418 4,063,321 4,063,321,418 4,063,321

126,547,389,518
6,327,370
126,547,389,518
6,327,370

‘D’ Deferred shares of £0.000001 each

2,482,747,137,178
2,482,747
2,482,747,137,178
2,482,747

Total

14,246,496

14,099,257

Ordinary and deferred shares were recorded as equity.

As at June 30, 2026, the Company had 347 pre-funded warrants outstanding over ADS’s (December 31, 2025 : 294,825*).

*Number of ADS warrants has been adjusted to reflect the ADS ratio change of ADSs to ordinary shares that occurred on 6 April 2026

On April 6, 2026, the Company effected a ratio change in the number of Ordinary Shares represented by ADSs from 100,000 Ordinary Shares per ADS to 500,000 Ordinary Shares per ADS. Number of warrants at December 31, 2025, reflect the impact of the ratio change.

In accordance with the Articles of Association for the Company adopted on 11 June 2025, the share capital of the Company consists of an unlimited number of ordinary shares of nominal value £0.000001 each. Ordinary and deferred shares were recorded as equity.

7.   Related party transaction

The Directors consider there to be no related party transactions during the periods reported other than Directors Remuneration.

8.   Contingent liabilities

Under the terms of the license agreement with Otsuka, the Group may be required to make additional milestone payments contingent on the achievement of specified development and regulatory events. These payments are dependent on future clinical and regulatory outcomes which are uncertain and not wholly within the Group’s control. At June 30, 2026, no liability has been recognized for the regulatory contingent milestone payments as the relevant obligating events had not occurred and an outflow of economic resources was not considered probable. No liability has been recognized for the development contingent milestone payments as the relevant obligating event had not occurred, however an outflow of economic resources is considered possible. The potential undiscounted amount payable under the agreement for development milestones is $0.5 million. The Group will recognize any such amounts when the relevant recognition criteria under IFRS are met.

9.   Events after the reporting date

On July 1, 2026, the Company completed a fundraise as detailed in the Financial Review raising gross proceeds of $3.5 million. The proceeds are expected to be used to support the Group’s development programs and for general working capital purposes.

On July 29, 2026, the Company held a General Meeting at which resolutions were proposed to reorganize the Company’s ordinary share capital, as a result of the exceptionally large number of ordinary shares in issue. All resolutions were passed at the meeting. The reorganization rationalized the Company’s share capital by reducing the number of ordinary shares in issue, without altering shareholders’ rights or their proportionate ownership of the Company. Under the reorganization, every 10,000 existing ordinary shares of £0.000001 each in the capital of the Company were consolidated into one consolidated ordinary share of £0.01 each. Each consolidated ordinary share of £0.01 was then subdivided and redesignated into one new ordinary share of £0.000001 and 9,999 E deferred shares of £0.000001 each.

Frontline plc (the “Company” or “Frontline”) (NYSE: FRO – OSE: FRO) refers to its announcement on August 4, 2026 regarding the sale of two VLCCs. Following the completion of the sale of the two VLCCs, the Board of Directors has declared a special one-time dividend of $0.80 per share, in line with Frontline’s core strategy of returning cash to our shareholders. The special one-time dividend comes in addition to the previously declared dividend of $2.61 per share for the second quarter of 2026.

The record date for the dividend will align with the previously declared dividend for the second quarter of 2026, thus it will be September 18, 2026, the ex-dividend date is expected to be September 17, 2026, for shares listed on the Oslo Stock Exchange and September 18, 2026, for shares listed on the New York Stock Exchange, and the dividends are scheduled to be paid on or about September 28, 2026.

September 11, 2026

The Board of Directors
Frontline plc.
Limassol, Cyprus

Questions should be directed to:

Lars H. Barstad: Chief Executive Officer, Frontline Management AS
+47 23 11 40 00

Inger M. Klemp: Chief Financial Officer, Frontline Management AS
+47 23 11 40 00

Forward-Looking Statements

Matters discussed in this announcement may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements, which include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

Frontline and its subsidiaries, desire to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. This announcement and any other written or oral statements made by Frontline or its behalf may include forward-looking statements, which reflect its current views with respect to future events and financial performance and are not intended to give any assurance as to future results. When used in this document, the words “believe,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “plan,” “potential,” “will,” “may,” “should,” “expect” and similar expressions, terms or phrases may identify forward-looking statements.

The forward-looking statements in this announcement are based upon various assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and data available from third parties. Although Frontline believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond Frontline’s control, it cannot assure you that Frontline will achieve or accomplish these expectations, beliefs or projections. Frontline undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to these important factors and matters discussed elsewhere herein, important factors that, in Frontline’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the parties’ ability to obtain the necessary regulatory approvals and to meet other closing conditions to complete the transactions referenced herein, as well as important factors described from time to time in the reports and other documents, including filings with the U.S. Securities and Exchange Commission.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.

Conference Call and Webcast Details:

September 14, 2026

  • English-language at 8:00 a.m. ET. / 2:00 p.m. CET

Webcast link:
https://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480
Phone number: +1 (800) 717 1738 or +1 (646) 307 1865
France Toll Free: +33 (800) 945 120

  • French-language at 9:00 a.m. ET. / 3:00 p.m. CET

Webcast link:
https://viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca
Phone number: +1 (800) 717 1738 or +1 (646) 307 1865
France Toll Free: +33 (800) 945 120

A replay will be available on the Company’s website following the event.  

About Cellectis     
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.  

For further information on Cellectis, please contact:         
     
Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, 
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com
Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

HAVERTOWN, Pa., Sept. 11, 2026 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $276,000, or $0.05 per diluted share, for its 2027 fiscal first quarter ended July 31, 2026 compared to net income of $4,692,000, or $0.87 per diluted share, for the same period of the prior year. Revenues were $6,051,000 for the first quarter of 2027 and $17,851,000 for the first quarter of 2026.

More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (www.amrepcorp.com/sec-filings/). As a result of many factors, including the nature and timing of specific transactions and the type and location of land or homes being sold, revenues, average selling prices and related gross margins from land sales or home sales can vary significantly from period to period and prior results are not necessarily a good indication of what may occur in future periods.

AMREP Corporation, through its subsidiaries, is a major holder of land, leading developer of real estate and award-winning homebuilder in New Mexico.

FINANCIAL HIGHLIGHTS

  Three Months Ended July 31,
  2026   2025
Revenues $ 6,051,000   $ 17,851,000
           
Net income $ 276,000   $ 4,692,000
Income per share – basic $ 0.05   $ 0.88
Income per share – diluted $ 0.05   $ 0.87
           
Weighted average number of common shares outstanding – basic   5,337,000     5,326,000
Weighted average number of common shares outstanding – diluted   5,393,000     5,375,000

CONTACT: Adrienne M. Uleau
  Chief Financial Officer and Vice President
  (610) 487-0907

VANCOUVER, British Columbia, Sept. 11, 2026 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, today announced that Karen Narwold will resign from the Company’s Board of Directors (the “Board”), effective September 15, 2026, following her acceptance of a new executive position and the increased time commitments associated with her new role.

“We thank Karen for her valuable contributions and commitment to Standard Lithium during her tenure on our Board,” said Bob Cross, Independent Chairman of Standard Lithium. “We congratulate her and wish her continued success in this next chapter of her career.”

Following Ms. Narwold’s resignation, the Board will consist of eight directors. The Company has initiated a search process for a new independent director that will complement the Board’s existing experience and expertise and support Standard Lithium’s continued growth and strategic objectives. The Company intends to announce an appointment following the conclusion of this process.

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes projects characterized by high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated direct lithium extraction and purification process. The Company’s flagship projects are in the Smackover Formation, an attractive lithium brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor, Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and actively advancing a promising lithium brine resource position in East Texas, including the highest known lithium brine grade project in North America, the Franklin project.

Standard Lithium trades on both the TSX Venture Exchange (“TSXV”) and the NYSE American under the symbol “SLI”. Visit the Company’s website at www.standardlithium.com for more information.

Investor Inquiries
Daniel Rosen
+1 604 409 8154
investors@standardlithium.com

Media Inquiries
media@standardlithium.com

X: @standardlithium
LinkedIn: https://www.linkedin.com/company/standard-lithium/

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “expect”, “plan”, “intend”, “may”, “will” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the Company’s intended timeline for onboarding an additional independent director, any new independent director’s ability to complement the Board’s existing experience and expertise, the accuracy of mineral or resource exploration activity at the Company’s flagship projects, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

CAMPBELL, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading technology provider for accelerating semiconductor creation in the AI era, today announced that the company’s board of directors has granted equity awards to Saurabh Sinha, the company’s Chief Financial Officer, as inducement awards material to Mr. Sinha’s acceptance of employment with the company under the company’s 2022 Employment Inducement Incentive Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards consist of (i) restricted stock units (RSUs) with a target grant value of $3,700,000, covering 142,835 shares of the company’s common stock, and (ii) performance stock units (PSUs) with a target grant value of $1,000,000, covering a target of 38,604 shares of the company’s common stock. In each case, the number of shares subject to the award was determined by dividing the target grant value by the 30-day trailing average price of the company’s common stock immediately prior to the effective date of the grant.

The RSUs vest as to 25% of the underlying shares on the first anniversary of the grant date, with the remainder vesting pro rata by day on the first day of each of the 12 consecutive fiscal quarters thereafter, aligned with fiscal quarterly vesting commencing January 1, 2028, in each case subject to Mr. Sinha’s continued service with the company through the applicable vesting date.

The PSUs vest upon satisfaction of two performance conditions: (i) the company achieving annual trailing four quarters’ publicly reported revenue of $200,000,000 or greater at any time on or before December 31, 2030; and subsequently (ii) the company’s common stock achieving a closing share price of $65 or greater, calculated as an average over a trading period of 15 trading days, at any time on or before December 31, 2031, in each case subject to Mr. Sinha’s continued service with the company through the applicable vesting date. In the event a change in control of the company occurs prior to the date the performance goals have been achieved, the PSUs shall not vest, and shall be forfeited for no consideration, effective upon the consummation of the change in control.

Mr. Sinha has entered into the company’s Form of Executive Change in Control Severance Agreement, which provides for full accelerated vesting of any unvested equity awards (except for any performance awards, including the PSUs, which are governed by the terms of the applicable award agreement) in the event of Mr. Sinha’s termination without cause or resignation for good reason during the period commencing three months prior to a change in control of the company and ending on the 12-month anniversary following such change in control.

The effective grant date of the awards was September 8, 2026, Mr. Sinha’s start date with the company, and the awards were approved by the company’s board of directors.

About Arteris

Arteris is a leading provider of semiconductor technology that accelerates the creation of high-performance, power-efficient silicon with built-in safety, reliability, and security. Innovative Arteris products are designed to optimize data movement and help ease complexity in the modern AI era with network-on-chip (NoC) interconnect intellectual property (IP), system-on-chip (SoC) software for integration automation and hardware security assurance. All are used by the world’s top technology companies to improve overall performance and engineering productivity, reduce risk, lower costs, and bring cutting-edge designs to market faster. Learn more at arteris.com.

© 2004–2026 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

Investor Contacts:
Arteris
Saurabh Sinha
Saurabh.Sinha@arteris.com

Sapphire Investor Relations, LLC
Erica Mannion and Michael Funari
+1 617 542 6180
IR@arteris.com

Media Contact:
Gina Jacobs
Arteris
+1 408 560 3044
newsroom@arteris.com

This press release was published by a CLEAR® Verified individual.

The Class A ordinary shares will trade under the symbol “RNAQ” and the warrants under the symbol “RNAQW” on The Nasdaq Capital Market, while units that are not separated will continue to trade under the symbol “RNAQU.”

NEW YORK, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) — Rainier Acquisition Corporation (Nasdaq: RNAQU) (the “Company”) announced today that, commencing September 14, 2026, holders of the units sold in its initial public offering (the “Units”) may elect to separately trade the Class A ordinary shares and warrants included in the Units. Each Unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. No fractional warrants will be issued upon separation of the Units, and only whole warrants will trade. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants are exercisable.

The Class A ordinary shares and warrants that are separated will begin trading on The Nasdaq Capital Market (“Nasdaq”) on September 15, 2026 under the symbols “RNAQ” and “RNAQW,” respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “RNAQU.” Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Class A ordinary shares and warrants.

The Units began trading on Nasdaq on August 27, 2026. The Company’s initial public offering, including the full exercise of the underwriter’s over-allotment option, totaled 8,625,000 Units and generated gross proceeds of $86,250,000, before underwriting discounts and offering expenses, and an aggregate of $86,250,000 ($10.00 per Unit) was placed in the Company’s trust account. Chardan Capital Markets LLC (“Chardan”) acted as the sole book-running manager for the offering.

About Rainier Acquisition Corporation

Rainier Acquisition Corporation (Nasdaq: RNAQU, RNAQ, RNAQW) is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company’s management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer. The Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available at www.sec.gov.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at prospectus@chardan.com.

A registration statement relating to these securities was declared effective by the SEC on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties, including with respect to the timing of separate trading and the Company’s search for an initial business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and related prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Rainier Acquisition Corporation
Gbola Amusa, MD, CFA, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
gamusa@rainier-acq.com

ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options are scheduled to vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates. The stock options have a ten-year term and an exercise price of $1.29, the closing price of MaxCyte’s common stock as reported by Nasdaq on August 31, 2026.

The RSUs are scheduled to vest over four years, with 25% vesting on the first anniversary of August 31, 2026 and the remainder vesting in three equal annual installments thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates.

MaxCyte is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. 

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
Erik Abdow
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

IMPORTANT NOTICE – DISCLAIMER

Not for release or distribution or publication in whole or in part, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. These materials do not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Australia, Canada, Japan or the Republic of South Africa.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to U.S. persons absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No offering of securities is being made in the United States or to U.S. persons.

ATHENS, Greece, Sept. 11, 2026 (GLOBE NEWSWIRE) — “AXIA Ventures Group Ltd”, member of the Alpha Bank Group, acting as Lead Advisor and Joint Coordinator and Bookrunner and “National Bank of Greece S.A.”, acting as Co-Advisor and Joint Coordinator and Bookrunner, in connection with the Public Offering in Greece and the admission to parallel listing of all common, registered, voting shares of “Star Bulk Carriers Corp.” (the “Company”), for trading on the Main Market the Regulated Securities Market of Euronext Athens, following the completion of the Public Offering on Friday, 11 September 2026, hereby announce, in accordance with article 17(2) and article 21(2) of Regulation (EU) 2017/1129, that a total of 4,400,000 new, common, registered, voting shares of the Company were allocated (the “New Shares”), including the shares of the parallel offering to a limited group of persons, in accordance with decision no. 4/379/18.04.2006 of the Board of Directors of the Hellenic Capital Market Commission.

The final offering price of the Company’s New Shares was determined at €24.50 (US$ 28.40)1 per New Share and is the same for all investors, Qualified and Retail, who participated in the Public Offering and the Parallel Offering.

The total valid demand expressed in the context of the Public Offering amounted to 26,788,512 shares, at the final offering price of €24.50 (US$ 28.40)1 per New Share, i.e. a total value of €656.3 million, resulting in the Public Offering being oversubscribed by over 6 times.

Detailed information regarding the allocation of the New Shares offered through the Public Offering by investor category will be announced on Tuesday, 15 September 2026.

The New Shares have not been, and will not be, registered under the U.S. federal securities laws or the securities laws of any other jurisdiction, and the New Shares may not be offered or sold in the United States or to U.S. persons unless an exemption from the registration requirements of the Securities Act is available. The New Shares are being offered and sold to non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.

Friday, 11 September 2026

Important Notice – Disclaimer

This announcement includes “forward-looking statements,” with respect to our expectations or beliefs concerning future events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “would,” “will,” “could,” “should,” “may,” “forecasts,” “potential,” “continue,” “possible” and similar expressions or phrases may identify forward-looking statements.

All forward-looking statements involve risks and uncertainties. The occurrence of the events described depend on many factors, some or all of which are not predictable or within our control. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, market conditions, disruptions to the mechanics required to operate cross-border trading, disruptions to trading on Euronext Athens, and other technical impediments to the commencement of trading. All future written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We undertake no obligation, and specifically decline any obligation, except as required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


1 The Offering Price has been converted into U.S. dollars based on the Euro/U.S. dollar (EUR/USD) exchange rate as of 11.09.2026 (€1 = 1.1592 USD). (Source: “European Central Bank” at Greek market close).

Contacts

Company: Investor Relations / Financial Media:
Simos Spyrou, Christos Begleris Nicolas Bornozis
Co ‐ Chief Financial Officers President
Star Bulk Carriers Corp. Capital Link, Inc.
c/o Star Bulk Management Inc. 230 Park Avenue, Suite 1540
40 Ag. Konstantinou Av. New York, NY 10169
Maroussi 15124 Tel. (212) 661‐7566
Athens, Greece E‐mail: starbulk@capitallink.com
Email: info@starbulk.com www.capitallink.com
www.starbulk.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.